RecruitingPhase 1NCT07519655
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Studying Malignant germ cell tumor of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-08046033(drug)
- Enrollment
- 250 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (6)
- Presbyterian/St Lukes Medical Center, Denver, Colorado, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Sarah Cannon Research Institute- Pharmacy, Nashville, Tennessee, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Hospital Oncologico Dr. Isaac Gonzalez-Martinez, Rio Piedras, Puerto Rico
- Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07519655 on ClinicalTrials.govOther trials for Malignant germ cell tumor of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06177964Lerapolturev (PVSRIPO) in GBMDarell Bigner
- RECRUITINGPHASE2NCT05483400Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsUniversity Medical Center Groningen
- ACTIVE NOT RECRUITINGNCT02724488Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesUniversity Health Network, Toronto
See all trials for Malignant germ cell tumor of the cervix uteri →